Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Interest & Investment Income: 2020-2024

Historic Interest & Investment Income for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $10.6 million.

  • Monte Rosa Therapeutics' Interest & Investment Income fell 5.05% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 14.60%. This contributed to the annual value of $10.6 million for FY2024, which is 13.20% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Interest & Investment Income is $10.6 million, which was up 13.20% from $9.3 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Interest & Investment Income high stood at $10.6 million for FY2024, and its period low was $9,000 during FY2020.
  • Moreover, its 3-year median value for Interest & Investment Income was $9.3 million (2023), whereas its average is $7.9 million.
  • Data for Monte Rosa Therapeutics' Interest & Investment Income shows a peak YoY spiked of 8,082.61% (in 2022) over the last 5 years.
  • Monte Rosa Therapeutics' Interest & Investment Income (Yearly) stood at $9,000 in 2020, then soared by 411.11% to $46,000 in 2021, then surged by 8,082.61% to $3.8 million in 2022, then spiked by 147.98% to $9.3 million in 2023, then increased by 13.20% to $10.6 million in 2024.